PepGen Presents Data from its Duchenne Muscular Dystrophy Program at the Muscular Dystrophy Association Clinical and Scientific Conference March 19 - March 22, 2023 Supporting Materials Nonclinical Data Demonstrate the Potential of the Enhanced Delivery Oligonucleotide (EDO) PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy 3.3 MB
Nonclinical Data Demonstrate the Potential of the Enhanced Delivery Oligonucleotide (EDO) PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy 3.3 MB
